Simvastatin in severe hypercholesterolaemia: a placebo controlled trial

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Biochemistry

Background:

• Severe primary hypercholesterolaemia poses significant cardiovascular risks.
• Effective lipid-lowering therapies are crucial for managing this condition.
• Statins are a cornerstone treatment for hypercholesterolaemia.

Purpose of the Study:

• To assess the efficacy and safety of simvastatin in patients with severe primary hypercholesterolaemia.
• To evaluate the impact of simvastatin on lipid profiles and related biomarkers.
• To determine simvastatin's effect on leucocyte HMG-CoA reductase activity.

Main Methods:

• A double-blind, placebo-controlled, parallel-group trial involving 27 patients.
• Daily administration of simvastatin 40 mg versus placebo.
• Measurement of total serum cholesterol, LDL-cholesterol, triglycerides, HDL-cholesterol, VLDL-cholesterol, apoprotein B (ApoB), apoprotein A1, lipoprotein (a), fibrinogen, viscosity, blood pressure, and leucocyte HMG-CoA reductase activity.

Main Results:

• Simvastatin significantly reduced total serum cholesterol, LDL-cholesterol, and apoprotein B (ApoB).
• Significant percentage reductions in triglycerides and VLDL-cholesterol, and increases in HDL-cholesterol were observed.
• Leucocyte HMG-CoA reductase activity increased significantly after 3 months of treatment.
• No significant changes were noted in apoprotein A1, lipoprotein (a), fibrinogen, viscosity, or blood pressure.
• No severe adverse effects or changes in CK or AST levels were reported.

Conclusions:

• Simvastatin is effective in treating severe and resistant hypercholesterolaemia.
• The drug is well-tolerated in the short term.
• Simvastatin demonstrates potential as a therapeutic agent for managing severe lipid disorders.